Sea Mild Biotechnology Co., Ltd. (7516) Stock Statistics & Valuation Metrics
Total Valuation
Sea Mild Biotechnology Co., Ltd. has a market cap or net worth of TWD 142.69M. The enterprise value is ―.
- Market Cap
- TWD 142.69M
- Enterprise Value
- ―
Share Statistics
Sea Mild Biotechnology Co., Ltd. has 19,308,928 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 19,308,928
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Sea Mild Biotechnology Co., Ltd.’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 2.97%.
- Return on Equity (ROE)
- 0.07
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 2.97%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 5.80M
- Profits Per Employee
- 139.31K
- Employee Count
- 59
- Asset Turnover
- 1.05
- Inventory Turnover
- 3.71
Valuation Ratios
The current PE Ratio of Sea Mild Biotechnology Co., Ltd. is 21.11. Sea Mild Biotechnology Co., Ltd.’s PEG ratio is -0.31.
- PE Ratio
- 21.11
- PS Ratio
- 0.38
- PB Ratio
- 1.22
- Price to FCF
- -10.49
- Price to Operating Cash Flow
- 20.19
- PEG Ratio
- -0.31
Income Statement
In the last 12 months, Sea Mild Biotechnology Co., Ltd. had revenue of 341.94M and earned 8.22M in profits. Earnings per share was 0.46.
- Revenue
- 341.94M
- Gross Profit
- 89.20M
- Operating Income
- 7.41M
- Pretax Income
- 8.79M
- Net Income
- 8.22M
- EBITDA
- 30.81M
- Earnings Per Share (EPS)
- 0.46
Cash Flow
In the last 12 months, operating cash flow was 6.85M and capital expenditures -20.45M, giving a free cash flow of -13.61M billion.
- Operating Cash Flow
- 6.85M
- Free Cash Flow
- -13.61M
- Free Cash Flow per Share
- -0.73
Dividends & Yields
Sea Mild Biotechnology Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.54%
- Earnings Yield
- 4.32%
Stock Price Statistics
- Beta
- 0.54
- 52-Week Price Change
- -22.62%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 29.38
- Average Volume (3m)
- 37.63K
Financial Position
Sea Mild Biotechnology Co., Ltd. as a current ratio of 1.45, with Debt / Equity ratio of 111.00%
- Current Ratio
- 1.45
- Quick Ratio
- 1.07
- Debt to Market Cap
- 0.55
- Net Debt to EBITDA
- 1.09
- Interest Coverage Ratio
- 3.01
Taxes
In the past 12 months, Sea Mild Biotechnology Co., Ltd. has paid 571.00K in taxes.
- Income Tax
- 571.00K
- Effective Tax Rate
- 0.06
Enterprise Valuation
Sea Mild Biotechnology Co., Ltd. EV to EBITDA ratio is 7.60, with an EV/FCF ratio of -14.66.
- EV to Sales
- 0.54
- EV to EBITDA
- 7.60
- EV to Free Cash Flow
- -14.66
- EV to Operating Cash Flow
- 29.14
Balance Sheet
Sea Mild Biotechnology Co., Ltd. has TWD 75.07M in cash and marketable securities with TWD 121.46M in debt, giving a net cash position of -TWD 46.39M billion.
- Cash & Marketable Securities
- TWD 75.07M
- Total Debt
- TWD 121.46M
- Net Cash
- -TWD 46.39M
- Net Cash Per Share
- -TWD 2.40
- Tangible Book Value Per Share
- TWD 6.08
Margins
Gross margin is 27.30%, with operating margin of 0.98%, and net profit margin of 1.60%.
- Gross Margin
- 27.30%
- Operating Margin
- 0.98%
- Pretax Margin
- 1.76%
- Net Profit Margin
- 1.60%
- EBITDA Margin
- 7.05%
- EBIT Margin
- 0.98%
Analyst Forecast
The average price target for Sea Mild Biotechnology Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 6.86%
- EPS Growth Forecast
- -69.28%
